sorafenib has been researched along with Vitreoretinopathy, Proliferative in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hur, DY; Kim, D; Kim, JW; Kim, YS; Park, GB; Roh, KH; Sun, H; Yang, JW | 1 |
1 other study(ies) available for sorafenib and Vitreoretinopathy, Proliferative
| Article | Year |
|---|---|
Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Cell Movement; Cells, Cultured; DNA; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Herpesvirus 4, Human; Humans; Immunoblotting; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Tumor Necrosis Factor-alpha; Vitreoretinopathy, Proliferative | 2015 |